NDs carrying the RS1 gene-editing platform can enter human iPSC and perform gene editing; animal experiments have also shown that this platform can enter the retina and edit the RS1 gene, causing changes in the retina. In addition, the establishment of XLRS patient-PSCs and in vitro "functional 3D retinal" differentiation technology can be used as a cell model platform to verify.

1. Non-viral and highly biocompatible
2. Easy to metabolize and carry large size CRISPR / Cas9 components
3. Release methods expressed in cells or in vivo and used for gene editing
4. Establishment of patient-specific iPSC and in vitro functional 3D retina

Our technology is curable and highly bio-safe and can be standardized and produced in large quantities. Gene therapy will have a breakthrough impact. Effective therapeutic drugs will be developed for hereditary diseases, and iPSC will be used as a testing platform for different diseases. In addition, cooperation will be carried out to enhance the technology of gene editing therapy